Concepedia

Wilson Guzman

WG

Statistics

Publications

8

Citations

386

H-Index

8

Active since

2014

Affiliations

Xilio Therapeutics (United States)(Current)

Sage Therapeutics (United States)

Compass (United States)

Thomas Jefferson University

Center for Cancer Research

Wilson Guzman is an author at Xilio Therapeutics (United States) specializing in immunotherapy, cancer immunotherapy, and oncology.

ORCID

Publications per year

2014–2023

8

Publications

8

The immunocytokine NHS-IL12 as a potential cancer therapeutic

Jonathan K. Fallon, Robert M. Tighe, Giorgio Kradjian et al. · Oncotarget · 2014 · 159 citations · Full text

, , +17

Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models

Chunxiao Xu, Yanping Zhang, Alex Rolfe et al. · Clinical Cancer Research · 2017 · 79 citations

, , +17

Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity

Uğur Eskiocak, Wilson Guzman, Benjamin Wolf et al. · JCI Insight · 2020 · 47 citations · Full text

, , +17

CTX-8573, an Innate-Cell Engager Targeting BCMA, is a Highly Potent Multispecific Antibody for the Treatment of Multiple Myeloma

Jennifer Watkins-Yoon, Wilson Guzman, Amanda Oliphant et al. · Blood · 2019 · 40 citations

, , +13

XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer

Kurt A. Jenkins, Miso Park, Magali Pederzoli-Ribeil et al. · Journal for ImmunoTherapy of Cancer · 2023 · 18 citations · Full text

, , +17

1–5 of 8